Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN100 for Prevention of S. aureus Pneumonia
NCT02940626Phase 2Terminated
- Sponsor
- Arsanis
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in Staphylococcus aureus pneumonia comparing ASN100 with Placebo (2 arms). Primary endpoint: Incidence of S. aureus pneumonia at Day 22. Started Nov 2016; status: terminated.
02
Drugs
ASN100
03
Conditions
Staphylococcus aureus pneumonia
Beyond the preview
Go deeper on NCT02940626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940626.